Jasmine Lichfield
Global Medical Lead Astellas Pharma
Seminars
Monday 23rd February 2026
Delving Into Padcev-Keytruda Clinical Performance in Urothelial Cancer to Understand the Potential of ADC Combinations to Reshape Standard of Care Therapies
9:30 am
- Overviewing enfortumab vedotin (EV) and combining with pembrolizumab
- Reflecting on previous clinical data of EV in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
- Exploring recent clinical combination data of EV-pembrolizumab combinations with pembrolizumab in muscle-invasive bladder cancer
